Business
Femasys Hosts Congresswoman Lucy McBath at Georgia Headquarters
The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our
About this update from Femasys Inc.
[{"type":"text","content":"The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our advancements for women’s reproductive health\nATLANTA, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, hosted Congresswoman Lucy McBath, Georgia’s 7th district representative to the U.S. House of Representatives, for an informative tour of the Company’s facility headquartered in Suwanee, Georgia. Femasys Founder, President and Chief Executive Officer Kathy Lee-Sepsick said, “Women’s reproductive health continues to be underserved and underfunded across the country. We are encouraged by the continued dialogue with leaders like Congresswoman McBath around our improved solutions for accessible, effective, and affordable reproductive health options for women. We look forward to continued visits and new and extended conversations with stakeholders across government, healthcare, and advocates as we continue to push for better and less-invasive options for women in their reproductive journeys.” Femasys provides minimally-invasive solutions that share delivery platforms. It has four commercially available products: FemaSeed® – FDA-cleared, intratubal insemination, FemVue® – contrast-generating device, FemCath® – selective delivery catheter, and FemCerv® – endocervical tissue sampler. These products have also received regulatory approval in Canada and Europe under the EU MDR. The Company’s current lead product candidate in late-stage clinical development is FemBloc® – permanent birth control. About Femasys Femasys is a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic solutions, including a lead revolutionary product candidate and FDA-cleared products. FemaSeed® Intratubal Insemination, an innovative infertility treatment designed to deliver sperm directly where conception occurs, is FDA-cleared and has received regulatory approval in Canada and Europe under the EU MDR. FemBloc® permanent birth control in late-stage clinical development is the fi...